This chapter provides recent progress in developments of BiVO4- and Bi2Te3-based materials for high efficiency photoelectrodes and thermoelectric applications. The self-assembling nanostructured BiVO4-based materials and their heterostructures (e.g., WO3/BiVO4) are developed and studied toward high efficiency photoelectrochemical (PEC) water splitting via engineering the crystal and band structures and charge transfer processes across the heteroconjunctions. In addition, crystal and electronic structures, optical properties, and strategies to enhance photoelectrochemical properties of BiVO4 are presented. The nanocrystalline, nanostructured Bi2Te3-based thin films with controlled structure, and morphology for enhanced thermoelectric properties are also reported and discussed in details. We demonstrate that BiVO4-based materials and Bi2Te3-based thin films play significant roles for the developing renewable energy.
Part of the book: Bismuth
Alkaloids are distributed in plant kingdom and play important role in protection, germination as well as plant growth stimulants. Most of them are chiral compounds and are clinically administered as the racemic mixture, even though its enantiomers have been known to exert different pharmacological activity. Liquid chromatography using chiral stationary phases (CSP) proved to be an essential tool with a wide range of applications, including analysis of the stereochemistry of natural compounds. This review gives an overview of chiral separation alkaloids that were used in theoretical studies and/or applications in recent years. It shows the possibilities of polysaccharide CSPs have now also been established as the first-choice of chiral phases for enantiomer separation.
Part of the book: Current Topics in Chirality
Pneumonia is one of the most common infectious diseases and the fourth leading cause of death globally. According to US statistics in 2019, pneumonia is the most common cause of sepsis and septic shock. In the US, inpatient pneumonia hospitalizations account for the top 10 highest medical costs, totaling $9.5 billion for 960,000 hospital stays. The emergence of antibiotic resistance in the treatment of infectious diseases, including the treatment of pneumonia, is a globally alarming problem. Antibiotic resistance increases the risk of death and re-hospitalization, prolongs hospital stays, and increases treatment costs, and is one of the greatest threats in modern medicine. Drug-related problems (DRPs) in pneumonia - such as suboptimal antibiotic indications, prolonged treatment duration, and drug interactions - increase the rate of antibiotic resistance and adverse effects, thereby leading to an increased burden in treatment. In a context in which novel and effective antibiotics are scarce, mitigating DRPs in order to reduce antibiotic resistance is currently a prime concern. A variety of interventions proven useful in reducing DRPs are antibiotic stewardship programs, the use of biomarkers, computerized physician order entries and clinical decision support systems, and community-acquired pneumonia scores.
Part of the book: Pneumonia
Coronary artery disease (CAD) remains the leading cause of mortality among cardiovascular diseases, responsible for 16% of the world’s total deaths. According to a statistical report published in 2020, the global prevalence of CAD was estimated at 1655 per 100,000 people and is predicted to exceed 1845 by 2030. Annually, in the United States, CAD accounts for approximately 610,000 deaths and costs more than 200 billion dollars for healthcare services. Most patients with CAD need to be treated over long periods with a combination of drugs. Therefore, the inappropriate use of drugs, or drug-related problems (DRPs), can lead to many consequences that affect these patients’ health, including decreased quality of life, increased hospitalization rates, prolonged hospital stays, increased overall health care costs, and even increased risk of morbidity and mortality. DRPs are common in CAD patients, with a prevalence of over 60%. DRPs must therefore be noticed and recognized by healthcare professionals. This chapter describes common types and determinants of DRPs in CAD patients and recommends interventions to limit their prevalence.
Part of the book: Coronary Artery Bypass Grafting